The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.00
Bid: 1.75
Ask: 2.25
Change: -1.50 (-42.86%)
Spread: 0.50 (28.571%)
Open: 1.875
High: 2.25
Low: 1.75
Prev. Close: 3.50
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

Tue, 09th Nov 2021 22:01

(Alliance News) - The following is a round-up of updates by London-listed companies not separately reported by Alliance News:

----------

Shepherd Neame Ltd - Faversham, Kent-based brewer and pub chain - Cuts annual pretax loss to GBP16.4 million, narrowed from GBP21.0 million the year before. Revenue shrinks to GBP86.9 million, down 26% year-on-year from GBP118.2 million. Notes that beer volume has been resilient throughout the pandemic and new on-trade customers have been obtained since re-opening. Highlights encouraging start to the new financial year, with strong demand for food and accommodation since July. Drinks trade is also recovering since the return to offices in London from September.

"We are greatly encouraged by the customer response since re-opening and are confident that beer and pubs remain every bit as core to British life as pre-pandemic," says Chief Executive Jonathan Neame. "We face challenges ahead, particularly with supply chain and inflationary pressures. That said, we are confident that the long term fundamental drivers for the business remain strong, including the ongoing infrastructure investment in our heartland, anticipated local population growth, changes in consumer and workplace trends, and our position at the centre of the community."

----------

Nostrum Oil & Gas PLC - oil & gas company - Extends forbearance agreement to Nov 26 from Nov 9 previously. The exploration and production company, which operates in the Caspian Basin area in eastern Europe, entered forbearance talks back in August 2020 after failing to pay interest due on its 8.0% senior notes due 2022 and 7.0% senior notes due 2025. It then struck a deal in October 2020. At the time, Nostrum said the forbearances included agreeing not to accelerate the notes' obligations as a result of the missed interest payments. Since then the expiry of the forbearance has been extended several times.

----------

Amte Power PLC - developer and manufacturer of lithium-ion and sodium-ion battery cells - Awarded small grant by Scottish government as part of its aim to achieve zero emissions from heavy duty vehicles such as buses, lorries and construction vehicles. The project will involve AMTE designing a specific battery module for the Ultra Energy cell. Chief Executive Kevin Brundish comments: "The electric vehicle market has not surprisingly been a significant focus throughout COP26. The Scottish government have been at the forefront of this debate and we are delighted to be participating in the zero emission heavy duty vehicles project."

----------

System1 Group PLC - marketing and brand consultancy based in London - Files a complaint for trademark infringement against System1 LLC over the infringing use of its name. "The company takes the protection of its unique intellectual property very seriously and believes such ongoing and expanding use by the opposing party is likely to cause significant confusion with System1 Group PLC and its registered marks and, moreover, constitutes intentional infringement, in violation of relevant US federal and state trademark laws as well as trademark laws in the UK, the EU and other countries," the company explains. The consultancy firms adds it believes it has a "compelling" case against the opposing party.

----------

Travel Chapter Holdings PLC - Bideford, Devon-based online holiday rental platform - Postpones proposed initial public offering due to "market volatility". The travel firm was initial planning to float on the London Stock Exchange's AIM market in mid-November. "Although Travel Chapter received considerable institutional investor support for the group's business model, growth strategy and management team, the board and shareholders have decided that proceeding with an initial public offering in this period of market volatility is not in the best interests of the group and its stakeholders," the company announces. Travel Chapter owns the brand holidaycottages.co.uk.

----------

Crossword Cybersecurity PLC - Richmond, England-based cyber security and risk-focused technology commercialisation company - Partners with Darkbeam to help improve Crossword's third-party risk management platform, Rizikon. Crossword will integrate Darkbeam's cyber risk ratings into the platform, helping organisations to further minimise the risk of digital threat. Rizikon users will be able to see the headline cyber risk rating on each supplier's scorecard. Crossword Sales Director Sean Arrowsmith says: "We are very pleased to partner with Darkbeam and help Rizikon customers further understand and manage the cyber risks that may exist in their supply chains. All too often these risks are unknown and only exposed when a cyber event occurs."

----------

Beximco Pharmaceuticals Ltd - Bangladesh-based pharmaceutical company - Is to begin selling the world's first generic version of Merck's coronavirus pill, molnupiravir. The drug is the first anti-viral pill for Covid-19 that can be taken at home and was recently developed by US firms Ridgeback Biotherapeutics LP and Merck & Co Inc. Beximco's branded generic version of molnupiravir will be marketed as Emorivir. The drug is for people who have had a positive Covid test and have at least one risk factor for developing severe illness, such as obesity, being over the age of 60, diabetes or heart disease. The UK's Medicines & Healthcare products Regulatory Agency said the drug is safe and effective at reducing the risk of hospital admission and death in people with mild to moderate Covid who are at extra risk from the virus. As an oral treatment that can be administered at home, molnupiravir has the "potential to have a significant impact on the treatment paradigm for Covid-19", Beximco states.

"The launch of a generic version of molnupiravir, the world's first oral antiviral drug to treat Covid-19, is another example of Beximco Pharma's ability to rapidly respond to make affordable treatments available to patients suffering from Covid-19. This is a great achievement for the company and one which we believe could play an important role in combating the pandemic, especially in low- and middle-income countries where access to vaccines has been limited," comments Managing Director Nazmul Hassan.

----------

Induction Healthcare Group PLC - healthcare technology company - Wins two-year contract to provide communications services to support the virtualisation of the UK benefits system. The contract, awarded by the Department of Work and Pensions, includes options for the department to extend the agreement term for up to a further two years. The contract value is for up to GBP2.6 million for the initial two years, totalling up to GBP5.2 million for the full four years. Chief Executive of Induction James Balmain comments: "This is our first major contract outside of the healthcare space and exemplifies the versatility of Induction's platforms as we look to expand from the secondary healthcare market".

----------

Netcall PLC - Bedford-based customer engagement software provider - Redeems GBP3.5 million of its existing GBP7.0 million loan note with BGF. The loan note was issued by the company to part fund the acquisition of MatsSoft in August 2017 and is repayable on or before March 2025. The interest cost resulting from the early redemption is GBP300,000 and the repayment will reduce the annual interest costs of the loan note from GBP600,000 to GBP300,000, Netcall explains.

----------

Castillo Copper Ltd - Perth, Australia-based exploration company - Says it is seeing "significant advances" in progressing its operations in Queensland and Zambia. Has samples collected and assessed for the extent of pegmatite outcropping at Picasso Lithium project, Western Australia. At its Luanshya project in Zambia, notes work now focused on formulating the inaugural drilling campaign. "We are pleased to report that we have made significant advances on several fronts in our copper operations in Queensland and Zambia. Specifically, the team on site at the Arya Prospect have overcome harsh conditions to progress our pioneering drilling campaign forward," comments Managing Director Simon Paull.

----------

Faron Pharmaceuticals Oy - Turku, Finland-based clinical stage biopharmaceutical company - Awarded EUR3.8 million in damages in arbitration case against Rentschler Biopharma. The Arbitration Institute of the Stockholm Chamber of Commerce ruled in favour of Faron. Faron was seeking damages from Rentschler for the termination of an agreement concerning the manufacturing of acute respiratory distress syndrome drug Traumakine. In October 2019, Rentschler had terminated the agreement to manufacture the active ingredient in Traumakine. After investigation, Faron concluded that the termination of the agreement breached the underlying agreement between the parties.

----------

BlueRock Diamonds PLC - Kareevlei diamond mine in the Kimberley region of South Africa - Reiterates confidence in achieving targeted production guidance of 22,000 to 26,000 carats, having produced 19,362 carats as at November 3. Says the Company is focused on completing an expansion project aimed at increasing tonnages at Kareevlei to provide the economies of scale to turn the mine into a "highly cash generative asset". Highlights "significant cost and operating efficiency benefits" anticipated once the new plant is running at capacity.

----------

Genedrive PLC - molecular diagnostics company - Narrows annual loss to GBP700,000 from GBP19.4 million the prior year. Revenue falls back below the million mark to GBP687,000 from GBP1.1 million. Notes short term outlook is centred on launch of two POC products: AIHL and CoV-POC. "We are at an exciting phase for the company with both the AIHL and CoV-POC products about to enter their commercial stages. Our balance sheet is strengthened following the recent equity raise and we are well placed to drive shareholder value going forwards," explains Chief Executive David Budd.

----------

AEW UK REIT PLC - UK commercial property investor - Buys 12 acre Central Six Retail Park in Coventry for GBP16.4 million. The purchase price reflects a net initial yield of around 11%, with an anticipated reversionary yield of circa 12.5%, AEW highlights. "At present the retail warehouse sector is providing some interesting opportunities, often underpinned by alternative use value, and occupied by tenants that have shown resilience during the pandemic. We are pleased to add this asset to the portfolio and will continue to target acquisitions where we believe valuations offer the opportunity to deliver both strong income and capital performance," says Portfolio Manager Alex Short.

----------

SVM UK Emerging Fund PLC - investor in small listed companies in the UK - Outperforms interim net asset value benchmark in a resilient first half. In the six months ended September 30, net asset value gained 17% to 145.7p per share, compared to a return of 8.4% at 125.00p on Mar 31 in the IA UK All Companies Sector Average Index. Growth was underpinned by positive contributions from Watches of Switzerland, Alpha FX Group, Dianomi, Reach and Dechra Pharmaceuticals. "The sharp recovery in the UK economy is creating value in some disruptive businesses," notes Chair Peter Dicks.

----------

Fidelity Special Values PLC - aims for capital growth by investing in special situations - Hikes full year dividend to 6.67 pence, an increase of 15% over the dividend of 5.80 pence paid in the prior year. The payout uplift follows net asset value growth of 56% for the year ended August 31, outperforming the benchmark index, which returned 27%. NAV per share hit 304.79p at year end, from 199.81p the previous year. "The year under review was an extraordinary one, in terms of the global and external factors affecting the companies in which we invest, the broader market, the daily lives of our shareholders, and their personal investments. This in turn led to extraordinary changes in investor confidence and sentiment leading to a remarkable, if uneven, recovery of asset prices," comments Chair Andy Irvine.

----------

Amryt Pharma PLC - biopharmaceutical company focused on developing novel treatments for rare diseases - Last Wednesday, reaffirms full year revenue guidance in range between USD220 million and USD225 million. The forecast revenue range would represent annual growth between 20% and 23%. Amryt posts third quarter revenue of USD56.5 million, up 15% year-on-year. Gross profit grows to USD29.3 million from USD22.3 million a year before. "Overall, the results demonstrate the strong growth we are experiencing across our business and represent our seventh consecutive quarter of positive earnings before interest, tax, depreciation and amortisation generation and this performance has been delivered despite the challenging Covid pandemic," says Chief Executive Joe Wiley.

----------

Standard Life Investments Property Income Trust Ltd - commercial property investor - Last Thursday, maintains third quarter dividend at 0.8925 pence per share. For the quarter, net asset value per share rises to 93.1p on September 30, from 88.3p on June 30. Says portfolio valuation increased by 4.7% on a like-for-like basis during the three months.

----------

Asia Wealth Group Holdings Ltd - Asia-focused investor in wealth management businesses - Last Friday, posts a slight rise in interim pretax profit to USD123,000 from USD117,000 a year before. The improvement was principally attributed to higher revenue, which climbed 5.1% to USD940,000. States that the group is "continuing to forge new revenue generating relationships, as well as expanding revenue creating opportunities", and is seeking new partnerships with firms in the same and new sectors.

----------

By Will Paige; willpaige@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
Today 12:10

IN BRIEF: Genedrive completes placing portion of GBP6 million raise

Genedrive PLC - Manchester-based pharmacogenetic testing - Completes placing of 138.8 million new shares at 1.5 pence each, raising GBP2.1 million. The placing is part of an overall equity raise being run by Peel Hunt LLP. Late Thursday, Genedrive had said it will try to raise a minimum of GBP6.0 million, including offers to retail investors. If that minimum is not reached, then only the firm placing will go ahead. The placing and retail offer prices will be the same and represent a more than 50% discount to Genedrive's closing price on Thursday. The placing shares will almost double Genedrive's total, and the retail offers could see another 376.4 million new shares issued. It expects to call a general meeting for May 31 to approve the share issue.

Read more
Today 10:59

AIM WINNERS & LOSERS: Polarean wins deal; Genedrive completes placing

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
Today 07:00

IN BRIEF: Genedrive aims to raise at least GBP6 million in share offer

Genedrive PLC - Manchester-based pharmacogenetic testing company - Seeks to raise a minimum of GBP6.0 million from an offer of new shares at 1.5 pence each. The announcement is made after the London market close on Thursday, and the price represents a more than 50% discount to Genedrive's closing price. The equity raise will be split into a firm placing of shares for GBP2.5 million, an offer to new and existing retail investors via the REX platform for GBP3.5 million, and an open offer to existing shareholders for GBP2.1 million. Genedrive says that if the GBP6.0 million minimum target is not reached, then only the firm placing will go ahead. The share sale is being run by broker Peel Hunt LLP.

Read more
24 Apr 2024 17:26

Genedrive enters clinical trial deal in US for MT-RNR1 US approval

(Alliance News) - Genedrive PLC on Wednesday said it has entered into a clinical trial agreement to support clinical studies to progress the regulatory approval of its MT-RNR1 product.

Read more
3 Apr 2024 16:54

LONDON MARKET CLOSE: FTSE 100 up thanks to US economic data

(Alliance News) - Stock prices in London closed mostly higher on Wednesday, after some data from the US reinforced the interest rate cut trajectory across the Atlantic.

Read more
3 Apr 2024 13:54

Genedrive shares jump on NICE test recommendation

(Sharecast News) - Genedrive shares were surging on Wednesday, after it received a significant endorsement from the UK's National Institute for Health and Care Excellence (NICE) regarding its 'CYP2C19-ID' test.

Read more
3 Apr 2024 11:49

Genedrive shares surge as UK's NICE backs test for ischaemic stroke

(Alliance News) - Genedrive PLC on Wednesday praised the National Health Service's work on strokes and mini strokes as a test by the company received a recommendation from the UK's National Institute for Health & Care Excellence.

Read more
3 Apr 2024 10:47

AIM WINNERS & LOSERS: UK NICE backs Genedrive test; Corero renews deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
28 Mar 2024 14:35

EARNINGS AND TRADING: 888 advances US exit; Arrow ups reserve estimate

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
15 Mar 2024 14:27

Genedrive receives R&D tax credit, plans fundraise

(Sharecast News) - Point-of-care pharmacogenetic testing company Genedrive announced the receipt of a research and development tax credit totalling £0.8m on Friday, taking its unaudited cash balances to £1.2m.

Read more
15 Mar 2024 13:50

Genedrive down as plans equity raise despite GBP800,000 tax credit

(Alliance News) - Genedrive PLC shares fell on Friday, after it said it has received a GBP800,000 research and development tax credit.

Read more
19 Feb 2024 18:57

TRADING UPDATES: Coro seals sale terms, Powerhouse makes good progress

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
19 Feb 2024 10:56

Genedrive set to apply for NICE EVA funding

(Sharecast News) - Genedrive shares rose on Monday, on the launch of the NICE early value assessment (EVA) evidence generation funding call, backed by the National Institute for Health and Care Research (NIHR).

Read more
19 Feb 2024 07:49

LONDON BRIEFING: MoneySupermarket credits Insurance for growth in 2023

(Alliance News) - Stocks in London are set to fall at Monday's open, as concerns over US inflation trends curb risk appetite, and damp hopes of interest rate cuts from the Federal Reserve.

Read more
2 Jan 2024 14:39

Genedrive confirms £0.6m equity prepayment drawdown

(Sharecast News) - Genedrive confirmed a planned £0.6m drawdown as part of its £5m equity prepayment facility on Tuesday, which it initially disclosed on 31 March 2023.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.